Biocon Gains India Approval for Liraglutide

  Published 1 year ago

Biocon Pharma received CDSCO approval for its generic Liraglutide, a drug for type 2 diabetes, using the streamlined '101 route'. This initiative aims to increase access to affordable diabetes treatment in India, where the disease has a high prevalence.

  • Generic version of Victoza approved in India.
  • Approval via CDSCO’s ‘101 route’ for faster access.
  • Addresses the growing diabetes epidemic in India.

You might like these

Thermax Surges on Margin Outlook

Brigade’s New Bengaluru Project

Arattai Surge Triggers Zoho Self‑Hosted Scaling

Uno Minda Acquires E-Drive Tech from Friwo

Indian Mutual Funds Foreign Assets Drop

Umiya Mobile Rajkot Store Launch 2025

TCS to Hike Pay for 80% Staff from Sept

News that matters the most ⚡